Clinical trials recruiting for ER Positive, HER2 Negative Breast Cancer
Phase breakdown
Drugs and treatments being studied
| Intervention | Trials |
|---|---|
| Camizestrant | 1 |
| Capecitabine | 1 |
| Ribociclib | 1 |
| SOC Chemotherapy | 1 |
| Tocilizumab/Tocilizumab Biosimilar | 1 |
Where trials are recruiting (top US states)
| State | Recruiting trials |
|---|---|
| Georgia | 2 |
| Kentucky | 2 |
| California | 1 |
| Illinois | 1 |
| Indiana | 1 |
| Nevada | 1 |
| New York | 1 |
| North Carolina | 1 |
| South Dakota | 1 |
| Tennessee | 1 |
| Texas | 1 |
| Virginia | 1 |
Top cities
Self-screener
Recruiting trials
- A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer
- Capecitabine in ER+/HER2-negative Breast Cancer
- Toci +/- SOC Chemo for Metastatic Triple Negative and ER-positive, HER2-negative Breast Cancers
Related conditions
Trials recruiting for ER Positive, HER2 Negative Breast Cancer often also study these conditions. Each links to its own recruiting-trial list.
Common questions
Are these trials free to join?
Study-related care in a clinical trial is usually provided at no cost to participants, and some trials reimburse travel. Costs vary by study - the trial team will explain what is and is not covered. Confirm this directly with them.
How do I know if I am eligible for ER Positive, HER2 Negative Breast Cancer trials?
Each trial lists inclusion and exclusion criteria. The screener above checks stated age and sex only. The full eligibility (your medical history, current medications, test results) is assessed by the study team. Open any trial to read its criteria, then contact the site.
Is this list complete?
No. For the full list, search ClinicalTrials.gov.